Herbal adaptogens combined with protein fractions from bovine colostrum and hen egg yolk reduce liver TNF-α expression and protein carbonylation in Western diet feeding in rats

Nutrition and Metabolism

Volumn 11, Issue 1, 2014, Pages

  Mobley, C Brooks ^a   Toedebusch, Ryan G ^b   Lockwood, Christopher M ^c   Heese, Alexander J ^b   Zhu, Conan ^b   Krieger, Anna E ^b   Cruthirds, Clayton L ^b   Hofheins, John C ^b   Company, Joseph M ^b   Wiedmeyer, Charles E ^b   Kim, Dae Y ^b   Booth, Frank W ^b,d,e   Roberts, Michael D ^a,b  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c 4Life Research   (United States)

^d University of Missouri   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

Author keywords

Inflammation; Liver; Oxidative stress; RNA seq

Indexed keywords

8 ISOPROSTANE; ALKALINE PHOSPHATASE; CALCIUM; CARBOHYDRATE; CREATININE; GLUCOSE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; BIOINFORMATICS; CALCIUM BLOOD LEVEL; CARBOHYDRATE METABOLISM; CATTLE; COLOSTRUM; CREATININE BLOOD LEVEL; DIET; EGG YOLK; GLUCOSE BLOOD LEVEL; HEN; LIPID LIVER LEVEL; LIPID STORAGE; LIPID TRANSPORT; LIVER; LIVER HISTOLOGY; MALE; MUSCLE MASS; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN CARBONYLATION; PROTEIN EXPRESSION; RAT; RNA ISOLATION; WESTERN DIET;

AVES; BOVINAE; RATTUS; RATTUS NORVEGICUS;

EID: 84900564794     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-11-19     Document Type: Article

References (53)

1. Hepatic lipid metabolism and non-alcoholic fatty liver disease. Tessari P, Coracina A, Cosma A, Tiengo A, Nutr Metab Cardiovasc Dis 2009 19 291 302 10.1016/j.numecd.2008.12.015 19359149
2. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. De Vito R, Alisi A, Masotti A, Ceccarelli S, Panera N, Citti A, Salata M, Valenti L, Feldstein AE, Nobili V, Int J Mol Med 2012 30 49 56 22505182
3. Nonalcoholic fatty liver disease and the metabolic syndrome: clinical implications and treatment. Rahimi RS, Landaverde C, Nutr Clin Pract 2013 28 40 51 10.1177/0884533612470464 23286927
4. Phenotyping the effect of diet on non-alcoholic fatty liver disease. de Wit NJ, Afman LA, Mensink M, Muller M, J Hepatol 2012 57 1370 1373 10.1016/j.jhep.2012.07.003 22796155
5. Lipotoxicity in NASH. Fuchs M, Sanyal AJ, J Hepatol 2012 56 291 293 21741924
6. Metabolic disturbances in non-alcoholic fatty liver disease. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH, Clin Sci 2009 116 539 564 10.1042/CS20080253 19243311
7. Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. Schuppan D, Schattenberg JM, J Gastroenterol Hepatol 2013 28 Suppl 1 68 76
8. The effect of lifestyle changes in non-alcoholic fatty liver disease. Centis E, Marzocchi R, Di Domizio S, Ciaravella MF, Marchesini G, Dig Dis 2010 28 267 273 10.1159/000282101 20460922
9. The ins and outs of mitochondrial dysfunction in NASH. Fromenty B, Robin MA, Igoudjil A, Mansouri A, Pessayre D, Diabetes Metabol 2004 30 121 138 10.1016/S1262-3636(07)70098-8 (Pubitemid 38715168)
10. High fat and high sucrose (western) diet induce steatohepatitis that is dependent on fructokinase. Ishimoto T, Lanaspa MA, Rivard CJ, Roncal-Jimenez CA, Orlicky DJ, Cicerchi C, McMahan RH, Abdelmalek MF, Rosen HR, Jackman MR, MacLean PS, Diggle CP, Asipu A, Inaba S, Kosugi T, Sato W, Maruyama S, Sánchez-Lozada LG, Sautin YY, Hill JO, Bonthron DT, Johnson RJ, Hepatology 2013 58 1632 1643 10.1002/hep.26594 23813872
11. Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. Zelber-Sagi S, Ratziu V, Oren R, World J Gastroenterol 2011 17 3377 3389 10.3748/wjg.v17.i29.3377 21876630
12. Current and emerging therapies in nonalcoholic fatty liver disease. Kashi MR, Torres DM, Harrison SA, Semin Liver Dis 2008 28 396 406 10.1055/s-0028-1091984 18956296
13. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Bugianesi E, Marzocchi R, Villanova N, Marchesini G, Best Pract Res Clin Gastroenterol 2004 18 1105 1116 10.1016/j.bpg.2004.06.025 15561641 (Pubitemid 39517695)
14. Antioxidant therapy in nonalcoholic steatohepatitis. Al-Busafi SA, Bhat M, Wong P, Ghali P, Deschenes M, Hepatitis Research and Treatment 2012 2012 947575 23227320
15. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F, Cochrane Database Syst Rev 2007 1 D004996 17253535
16. Antioxidants in bovine colostrum. Przybylska J, Albera E, Kankofer M, Reprod Domest Anim 2007 42 402 409 10.1111/j.1439-0531.2006.00799.x 17635778 (Pubitemid 47041840)
17. Nonalcoholic fatty liver disease: pathogenesis and the role of antioxidants. Mehta K, Van Thiel DH, Shah N, Mobarhan S, Nutr Rev 2002 60 289 293 10.1301/002966402320387224 12296456 (Pubitemid 35025794)
18. Etiopathogenesis of nonalcoholic steatohepatitis. Chitturi S, Farrell GC, Semin Liver Dis 2001 21 27 41 10.1055/s-2001-12927 11296694 (Pubitemid 32240484)
19. Update on nonalcoholic fatty liver disease. McCullough AJ, J Clin Gastroenterol 2002 34 255 262 10.1097/00004836-200203000-00013 11873108 (Pubitemid 34177381)
20. Regulation of oxidative stress and inflammation by hepatic adiponectin receptor 2 in an animal model of nonalcoholic steatohepatitis. Matsunami T, Sato Y, Ariga S, Sato T, Kashimura H, Hasegawa Y, Yukawa M, Int J Clin Exp Pathol 2010 3 472 481 20606728
21. Green tea extract attenuates hepatic steatosis by decreasing adipose lipogenesis and enhancing hepatic antioxidant defenses in ob/ob mice. Park HJ, DiNatale DA, Chung MY, Park YK, Lee JY, Koo SI, O'Connor M, Manautou JE, Bruno RS, J Nutr Biochem 2011 22 393 400 10.1016/j.jnutbio.2010.03.009 20655714
22. Green tea extract suppresses NFkappaB activation and inflammatory responses in diet-induced obese rats with nonalcoholic steatohepatitis. Park HJ, Lee JY, Chung MY, Park YK, Bower AM, Koo SI, Giardina C, Bruno RS, J Nutr 2012 142 57 63 10.3945/jn.111.148544 22157544
23. Resveratrol modulates autophagy and NF-kappaB activity in a murine model for treating non-alcoholic fatty liver disease. Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, Weng X, Food Chem Toxicol 2013 63 166 173 23978414
24. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Rivera L, Moron R, Zarzuelo A, Galisteo M, Biochem Pharmacol 2009 77 1053 1063 10.1016/j.bcp.2008.11.027 19100718
25. Resveratrol protects primary rat hepatocytes against oxidative stress damage: activation of the Nrf2 transcription factor and augmented activities of antioxidant enzymes. Rubiolo JA, Mithieux G, Vega FV, Eur J Pharmacol 2008 591 66 72 10.1016/j.ejphar.2008.06.067 18616940
26. Green tea extract protects against nonalcoholic steatohepatitis in ob/ob mice by decreasing oxidative and nitrative stress responses induced by proinflammatory enzymes. Chung MY, Park HJ, Manautou JE, Koo SI, Bruno RS, J Nutr Biochem 2012 23 361 367 10.1016/j.jnutbio.2011.01.001 21543212
27. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Gomez-Zorita S, Fernandez-Quintela A, Macarulla MT, Aguirre L, Hijona E, Bujanda L, Milagro F, Martinez JA, Portillo MP, Br J Nutr 2012 107 202 210 10.1017/S0007114511002753 21733326
28. Piperine, an LXRalpha antagonist, protects against hepatic steatosis and improves insulin signaling in mice fed a high-fat diet. Jwa H, Choi Y, Park UH, Um SJ, Yoon SK, Park T, Biochem Pharmacol 2012 84 1501 1510 10.1016/j.bcp.2012. 09.009 23000915
29. Effect of dietary resveratrol on the metabolic profile of nutrients in obese OLETF rats. Nagao K, Jinnouchi T, Kai S, Yanagita T, Lipids Health Dis 2013 12 8 10.1186/1476-511X-12-8 23374859
30. Dose translation from animal to human studies revisited. Reagan-Shaw S, Nihal M, Ahmad N, FASEB J 2008 22 659 661 17942826 (Pubitemid 351348146)
31. High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. VanSaun MN, Lee IK, Washington MK, Matrisian L, Gorden DL, Am J Pathol 2009 175 355 364 10.2353/ajpath.2009.080703 19541928
32. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. Li ZZ, Berk M, McIntyre TM, Feldstein AE, J Biol Chem 2009 284 5637 5644 10.1074/jbc.M807616200 19119140
33. Postprandial leucine and insulin responses and toxicological effects of a novel whey protein hydrolysate-based supplement in rats. Toedebusch RG, Childs TE, Hamilton SR, Crowley JR, Booth FW, Roberts MD, J Int Soc Sports Nutr 2012 9 24 10.1186/1550-2783-9-24 22672725
34. Effects of dietary aflatoxin on the hepatic expression of apoptosis genes in growing barrows. Rustemeyer SM, Lamberson WR, Ledoux DR, Wells K, Austin KJ, Cammack KM, J Anim Sci 2011 89 916 925 10.2527/jas.2010-3473 21415419
35. Deep RNA sequencing reveals novel cardiac transcriptomic signatures for physiological and pathological hypertrophy. Song HK, Hong SE, Kim T, Kim Do H, PLoS One 2012 7 35552 10.1371/journal.pone.0035552 22523601
36. RNA-seq reveals novel transcriptome of genes and their isoforms in human pulmonary microvascular endothelial cells treated with thrombin. Zhang LQ, Cheranova D, Gibson M, Ding S, Heruth DP, Fang D, Ye SQ, PLoS One 2012 7 31229 10.1371/journal.pone.0031229 22359579
37. RNA-seq analysis of synovial fibroblasts brings new insights into rheumatoid arthritis. Heruth DP, Gibson M, Grigoryev DN, Zhang LQ, Ye SQ, Cell Biosci 2012 2 43 10.1186/2045-3701-2-43 23259760
38. Texture analysis of liver fibrosis microscopic images: a study on the effect of biomarkers. Amin A, Mahmoud-Ghoneim D, Acta Biochim Biophys Sin 2011 43 193 203 10.1093/abbs/gmq129 21258076
39. Anti-inflammatory effects of chicanine on murine macrophage by down-regulating LPS-induced inflammatory cytokines in IkappaBalpha/MAPK/ERK signaling pathways. Chen H, Sohn J, Zhang L, Tian J, Chen S, Bjeldanes LF, Eur J Pharmacol 2013 724C 168 174
40. Effects of rhaponticum carthamoides versus glycyrrhiza glabra and punica granatum extracts on metabolic syndrome signs in rats. Dushkin M, Khrapova M, Kovshik G, Chasovskikh M, Menshchikova E, Trufakin V, Shurlygina A, Vereschagin E, BMC Complement Altern Med 2014 14 33 10.1186/1472-6882-14-33 24444255
41. Food selection based on total antioxidant capacity can modify antioxidant intake, systemic inflammation, and liver function without altering markers of oxidative stress. Valtuena S, Pellegrini N, Franzini L, Bianchi MA, Ardigo D, Del Rio D, Piatti P, Scazzina F, Zavaroni I, Brighenti F, Am J Clin Nutr 2008 87 1290 1297 18469252 (Pubitemid 351679771)
42. Postprandial plasma carotenoid responses following consumption of strawberries, red wine, vitamin C or spinach by elderly women. Paiva SA, Yeum KJ, Cao G, Prior RL, Russell RM, J Nutr 1998 128 2391 2394 9868186 (Pubitemid 29012988)
43. Antioxidant supplements in exercise: worse than useless? Gomez-Cabrera MC, Ristow M, Vina J, Am J Physiol Endocrinol Metab 2012 302 476 E477 author reply E478-479 10.1152/ajpendo.00567.2011 22307485
44. Oral administration of vitamin C decreases muscle mitochondrial biogenesis and hampers training-induced adaptations in endurance performance. Gomez-Cabrera MC, Domenech E, Romagnoli M, Arduini A, Borras C, Pallardo FV, Sastre J, Vina J, Am J Clin Nutr 2008 87 142 149 18175748
45. Dietary Fructus Schisandrae extracts and fenofibrate regulate the serum/hepatic lipid-profile in normal and hypercholesterolemic mice, with attention to hepatotoxicity. Pan SY, Yu Q, Zhang Y, Wang XY, Sun N, Yu ZL, Ko KM, Lipids Health Dis 2012 11 120 10.1186/1476-511X-11-120 22989092
46. Pck1 gene silencing in the liver improves glycemia control, insulin sensitivity, and dyslipidemia in db/db mice. Gomez-Valades AG, Mendez-Lucas A, Vidal-Alabro A, Blasco FX, Chillon M, Bartrons R, Bermudez J, Perales JC, Diabetes 2008 57 2199 2210 10.2337/db07-1087 18443203
47. Enhanced GLUT2 gene expression in an oleic acid-induced in vitro fatty liver model. Okamoto Y, Tanaka S, Haga Y, Hepatol Res 2002 23 138 144 10.1016/S1386-6346(01)00172-3 12048068 (Pubitemid 36113479)
48. CD36 genetics and the metabolic complications of obesity. Love-Gregory L, Abumrad NA, Curr Opin Clin Nutr Metab Care 2011 14 527 534 10.1097/MCO. 0b013e32834bbac9 21912245
49. Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice. Hajri T, Han XX, Bonen A, Abumrad NA, J Clin Invest 2002 109 1381 1389 10.1172/JCI0214596 12021254 (Pubitemid 34546903)
50. CD36 deficiency increases insulin sensitivity in muscle, but induces insulin resistance in the liver in mice. Goudriaan JR, Dahlmans VE, Teusink B, Ouwens DM, Febbraio M, Maassen JA, Romijn JA, Havekes LM, Voshol PJ, J Lipid Res 2003 44 2270 2277 10.1194/jlr.M300143-JLR200 12923231 (Pubitemid 38082485)
51. Muscle-specific overexpression of CD36 reverses the insulin resistance and diabetes of MKR mice. Héron-Milhavet L, Haluzik M, Yakar S, Gavrilova O, Pack S, Jou WC, Ibrahimi A, Kim H, Hunt D, Yau D, Asghar Z, Joseph J, Wheeler MB, Abumrad NA, LeRoith D, Endocrinology 2004 145 4667 4676 10.1210/en.2003-1543 15231693 (Pubitemid 39281460)
52. Sample size for detecting differentially expressed genes in microarray experiments. Wei C, Li J, Bumgarner RE, BMC Genomics 2004 5 87 10.1186/1471-2164-5-87 15533245 (Pubitemid 39565299)
53. Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M, Obesity (Silver Spring) 2008 16 2081 2087 10.1038/oby.2008.315 18551111